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Systems pathology by multiplexed 
immunohistochemistry and whole-
slide digital image analysis
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The paradigm of molecular histopathology is shifting from a single-marker immunohistochemistry 
towards multiplexed detection of markers to better understand the complex pathological processes. 
However, there are no systems allowing multiplexed IHC (mIHC) with high-resolution whole-slide tissue 
imaging and analysis, yet providing feasible throughput for routine use. We present an mIHC platform 
combining fluorescent and chromogenic staining with automated whole-slide imaging and integrated 
whole-slide image analysis, enabling simultaneous detection of six protein markers and nuclei, and 
automatic quantification and classification of hundreds of thousands of cells in situ in formalin-fixed 
paraffin-embedded tissues. In the first proof-of-concept, we detected immune cells at cell-level 
resolution (n = 128,894 cells) in human prostate cancer, and analysed T cell subpopulations in different 
tumour compartments (epithelium vs. stroma). In the second proof-of-concept, we demonstrated 
an automatic classification of epithelial cell populations (n = 83,558) and glands (benign vs. cancer) 
in prostate cancer with simultaneous analysis of androgen receptor (AR) and alpha-methylacyl-
CoA (AMACR) expression at cell-level resolution. We conclude that the open-source combination of 
8-plex mIHC detection, whole-slide image acquisition and analysis provides a robust tool allowing 
quantitative, spatially resolved whole-slide tissue cytometry directly in formalin-fixed human tumour 
tissues for improved characterization of histology and the tumour microenvironment.
It is important to understand the spatial cellular composition and heterogeneity of tissues, especially in cancer 
where cell subpopulations and the tumour microenvironment provide insights about the biology and clinical 
progression of the disease. The standard method for detecting proteins in situ is immunohistochemistry (IHC) 
on thin sections of formalin-fixed paraffin-embedded (FFPE) tissue followed by a visual assessment of antibody 
reactivity. However, as the analysis of multiple markers is performed on consecutive sections, it is impossible 
to assess co-localization of markers at single cell level, which radically limits accurate classification of cells that 
require detection of multiple markers (e.g. different subtypes of immune cells). In order to better understand the 
pathological processes and deliver more accurate prognostics and patient stratification for treatments, tumours 
should be characterized more comprehensively, integrating cell-level information with context specific informa-
tion of the microenvironment. However, the limitations of the traditional IHC have impeded the evolution of 
histopathology towards truly multi-parametric analysis of whole tissue sections.
In contrast to conventional IHC, multiplexed IHC (mIHC) enables multi-parametric readouts from a single 
tissue section. The current state-of-the-art employ either fluorescence1–9 or mass spectrometry10–12 detection. 
Although various sophisticated mIHC methods are available for FFPE material, the current applications have 
limited scalability and throughput, because, although showing high level of multiplexing, the analysis is limited 
to small region-of-interests and/or limited number of fields-of-views2,4,6–9,13–15. For example, >5-plex fluorescence 
assays utilizing multispectral imaging are slow in terms of image acquisition. One solution to overcome this lim-
itation is to utilize a “hotspot” imaging where a low-resolution scan of whole tissue is performed first followed 
by a subsequent “hotspot” analysis at higher resolution1,16. Nevertheless, this assay design does not allow true 
whole-slide analytics. Other promising technologies for fluorescence mIHC rely on dye cycling, namely MxIF5 
and CycIF17, which utilize fluorochrome bleaching and/or antibody stripping between staining cycles. The level 
of multiplexing of these “temporally” resolved assays is much higher than of the spectrally resolved assays, even 
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up to 61 markers per section17. However, major drawbacks of dye cycling are the laborious staining/imaging 
cycles5,17, the primary antibody labelling for direct fluorescence detection5,17, and potential changes of the tissue 
morphology and antigenicity due to the repetitive exposure of the tissue to the dye bleaching and/or antibody 
stripping conditions5. In contrast to fluorescence, mass spectrometry based methods provide highly multiplexed 
mIHC assays10–12,17 omitting most of the pitfalls of fluorescence imaging. Mass spectrometry holds a great poten-
tial for the future, but the instrumentation is still expensive, not easily accessible, and the spectrometry “image” 
acquisition is extremely slow, even when compared to multispectral fluorescence acquisition, being impractical 
for routine whole-slide analytics at cell-level resolution.
Despite of the issue in terms of scalability and throughput, multiplexed IHC (mIHC) methods allow 
simultaneous detection and co-localization analysis of multiple markers in situ in the intact spatial context of 
tissues1–15,17–19. Moreover, multiplexing allows for a simple and easily automated, marker-guided tissue segmenta-
tion (e.g. epithelium vs. stroma), and provides more information from each tissue section, which may be critically 
important for small samples, such as needle biopsies of tissues or small metastatic tumour samples. However, as 
tumours often exhibit significant cellular and spatial heterogeneity, it would be important to be able to perform 
high-resolution, multiplexed analysis across whole-sections of tumours20. Hence, there is a growing need for an 
integrated “workhorse” mIHC system enabling not only moderate degree of multiplexing but also imaging and 
image analysis for high-resolution whole-slide analytics.
Here, we describe a whole-slide 8-plex mIHC platform combining fluorescence (five-channel) and chromo-
genic (three-channel) mIHC allowing for a quantitative whole-slide analysis of six markers and cell nuclei at 
cell-level resolution. Our mIHC method is based on a fixed set of secondary reagents instead of labelled primary 
antibodies, thus enabling rapid implementation and virtually unlimited design of custom antibody panels for 
different targets of interest. We also provide protocols and methods for implementing new antibodies and tar-
gets for mIHC. As a proof-of-concept, we demonstrate automated classification of epithelial and immune cells 
in human prostate cancer and a simultaneous marker analysis at single cell level. To our knowledge, this is the 
first open-source 8-plex mIHC assay design that enables whole-slide imaging with true quantitative whole-slide 
analysis in FFPE samples at high resolution across the whole tissue.
Results
As a proof-of-concept, we applied the mIHC method for the whole-slide analysis of immune cells (Fig. 1) and 
prostate epithelial cells (Fig. 2) in human prostate cancer (PCa) samples. The method utilizes a combination 
of fluorescent and chromogenic tissue staining for the simultaneous detection of six proteins and nuclei in 
formalin-fixed tissue section (Supplementary Fig. S1 and Supplementary Fig. S2).
We designed an antibody panel for the detection and classification of immune cells (CD45, CD4, CD8, and 
FoxP3), including antibodies against pan-cytokeratin (Pan-CK) and epithelial cadherin (E-cadherin) as well as 
Ki67 to measure cell proliferation (Immune cell panel). The other panel was designed for the characterisation of 
prostate epithelium and consisted of antibodies for p63, Pan-CK, CK5, CK8, CK18, alpha-methylacyl-CoA race-
mase (AMACR), and androgen receptor (AR) (Epithelial cell panel).
Antibody validation for mIHC. We tested all primary antibodies used in the study in lymph node and 
prostate FFPE tissues. Epithelial markers CK18, CK8, CK5, p63, E-Cadherin, and Pan-CK were negative in lymph 
node (negative for epithelium) and positive in prostate epithelial cells. In contrast, immune cell markers CD4, 
CD8, CD45, and FoxP3 showed positive staining in lymph node whereas prostate epithelial cells were negative. 
The expression of AR was weak in some immune cells in lymph node and strong in prostate luminal epithelial 
cells. AMACR was expressed only in cancerous prostate cells. Ki67 was positive in lymph node germinal center 
but negative in well-differentiated prostate epithelium (Supplementary Fig. S3).
As the detection of the first pair of primary antibodies is based on tyramide signal amplification (TSA)18,21,22 
followed by an inactivating heating step and additional pair of primary antibodies (see Supplementary Fig. S2), 
it was important to assess antibody denaturation/stripping efficacy. To test if the primary antibodies are either 
detached from the tissue or denatured in situ by heating, we incubated the tissues with bound primary antibodies 
in a hot buffer recapitulating the conditions in the heat-induced epitope retrieval (HIER) protocol. First, we incu-
bated tissue-bound primary-secondary antibody complexes in hot buffer to see if the harsh conditions reduce flu-
orescence signal. After heating the anti-CK5/anti-rabbit-AlexaFluor555 complex (Tris-EDTA pH 9), we observed 
94% of the fluorescence intensity as compared to non-heated control. After subsequent heating in glycine (pH 
2), we observed 102% of the fluorescence intensity as compared to non-heated control. In case of the  anti-CK8/
anti-mouse-AlexaFluor647 complex, the corresponding fluorescence was 95% and 74% (Supplementary Fig. S4). 
Next, we performed an assay to detect antibody denaturation, first heating the tissue sections with bound primary 
antibodies in hot buffer and then detecting the primary antibodies using secondary antibodies. As most primary 
antibodies showed complete absence of DAB signal after heat exposure even at high antibody concentrations, 
but fluorescence signals were not significantly diminished after heating in the earlier experiments, we conclude 
that the primary antibodies (and secondary antibodies) are denatured, but not detached in the HIER conditions. 
E-cadherin (BD Biosciences 610182) and Ki67 (Abcam 92742) antibodies, however, were not completely dena-
tured upon the heating step (Supplementary Fig. S5). Hence, all the primary antibodies require testing for the 
denaturation efficacy.
mIHC performance. Next, we tested the fluorescence mIHC in terms of imaging and signal-to-background 
(S/B) performance. We designed a fluorescence imaging system with labels and optical filter sets including 
near infrared (NIR) detection (Supplementary Table S1) to maximise spectral resolution, yielding raw image 
data that do not require channel unmixing after image acquisition. The pairwise signal-to-background (S/B) 
ratios for AlexaFluor488 (30 ms exposure in FITC channel), AlexaFluor555 (40 ms exposure in CY3 channel), 
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Figure 1. Multiplexed immunohistochemistry for immune cells in prostate tumour (patient 1). (a) 
Fluorescence (FL) and brightfield (CHR) images are acquired and (b) registered using nuclei information 
from both images (Hoechst and haematoxylin). (c) Cell segmentation and classification is based on nuclei, 
epithelium marker expression (Pan-Epi = Pan-CK + ECad), and cell-type specific marker expression (CD45 for 
leukocytes). Scale bar 500 µm. CHR, chromogenic; FL, fluorescence; IHC, immunohistochemistry; Pan-CK, 
pan-cytokeratin; Pan-Epi; pan-epithelium.
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Figure 2. Multiplexed immunohistochemistry for epithelial cells in prostate tumour. (a) Fluorescence (FL) 
and brightfield (CHR) images were acquired and (b) images are registered using nuclei information from both 
images, namely Hoechst and haematoxylin. (c) Cell segmentation and classification is based on epithelium 
marker expression (Pan-Epi = Pan-CK + E-cadherin) and cell-type specific classifier marker expression in 
each prostate gland. A given gland is classified as cancerous if basal cell marker expression (CK5 + p63) is lost. 
Scale bar 500 µm. AMACR, alpha-methylacyl-CoA racemase; AR, androgen receptor; CK5, cytokeratin 5; 
CK8, cytokeratin 8; CK18, cytokeratin 18; CHR, chromogenic; FL, fluorescence; IHC, immunohistochemistry; 
Pan-CK, pan-cytokeratin; Pan-Epi; pan-epithelium.
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AlexaFluor647 (100 ms or 50 ms exposure in CY5 channel), and AlexaFluor750 (150 ms exposure in CY7 chan-
nel) were 51, 17 (with AF488) or 25 (with AF647), 9 (with AF555) or 11 (with AF750), and 6.3, respectively. With 
background noise thresholding (tissue autofluorescence) the corresponding ratios were 48, 15 or 23, 7 or 10, and 
3.8 (Supplementary Fig. S6).
Immune cell classification and analysis. For the classification of immune cells in prostate cancer epi-
thelium and stroma, we detected cells by nuclear staining, and identified leukocytes and epithelial cells using 
markers for pan-leukocyte (CD45) and pan-epithelium (Pan-Epi = pan-cytokeratin + E-cadherin). We classified 
the CD45+ leukocytes as stromal or epithelial depending on their location within the tissue segments, and fur-
their classified each leukocyte as T regulatory (CD4+FoxP3+CD8−), T helper (CD4+FoxP3−CD8−), or T effector 
(CD8+CD4−FoxP3−) cell.
A total of 128,894 cells were detected in a whole section of a prostate tumour (patient 1), consisting of 38% 
leukocytes, 40% epithelial cells, and 22% stromal cells (Fig. 3). Among leukocytes, 24% and 76% were within the 
prostate epithelium or stroma, respectively. We found significantly lower proportion of regulatory T cells (Treg) 
(1.8% vs. 5.7%, p < 0.0005) and helper T cells (Th) (11% vs. 22%, p < 0.0005) in the epithelium as compared to the 
stroma, whereas the proportion of effector T cells (Te) was almost the same in the epithelium and in the stroma 
(9.0% vs. 8.8%, p < 0.0005). However, the proliferation rate (Ki67+ cells) was almost three-fold for Treg cells 
(4.0% vs. 1.4%, p = 0.013) and double for Th cells (1.1% vs. 0.5%, p = 0.029) in the epithelium as compared to the 
stroma. All marker expression values are presented in Supplementary Table S2.
Epithelial cell classification and analysis. Next, we studied the composition of prostate tumour tissue 
using the Epithelial cell panel to detect prostate cells in individual prostatic glands and to automatically classify 
the detected cells as stromal, basal epithelial, benign luminal epithelial, or cancer cells. First, we segmented the 
epithelium and stroma and then classified epithelial glands as either benign or malignant based on the presence of 
CK5+p63+ basal cells. A gland was considered to be malignant in case of a complete absence of basal cells. Next, 
we segmented and classified individual cells as stromal, basal epithelial (Pan-CK+CK5+p63+), benign luminal 
epithelial (Pan-CK+CK5−p63− cells located in a benign gland), or cancer cells (Pan-CK+CK5−p63− cells located 
in a malignant gland).
We detected a total of 83,558 cells in a whole-section of a prostate cancer sample (patient 2), of which 46% and 
54% were epithelial and stromal cells, respectively (Fig. 4). Overall, we classified 20% of all cells as cancer, 11% 
as benign luminal, and 15% as basal cells. After classification, the expression of AMACR, AR, CK8, and CK18 
was measured in all cells (Supplementary Table S2). The cytokeratin analysis in individual cells revealed 68% 
stronger expression of CK18 in prostate cancer cells (n = 16,614) as compared to benign luminal cells (n = 9,576) 
(0.200 vs. 0.119, p < 0.001), whereas the expression of CK8 was only 14% higher in cancer cells (0.081 vs. 0.071, 
p < 0.001). Interestingly, we found that AR expression was 43% higher in AMACR− cancer cells (n = 11,511) 
than in AMACR+ cancer cells (n = 5,103) (0.160 vs. 0.112, p < 0.001) and 58% higher than in AMACR− benign 
luminal cells (n = 9,068) (0.160 vs. 0.101, p < 0.0005). However, AMACR+ benign luminal cells (n = 508) showed 
Figure 3. Tissue cytometry of immune cells (patient 1) in prostate cancer. (a) Cell class distribution and (b) 
CD45 and Pan-Epi expression in all cells (n = 128,894). (c) The proportion of different T cell classes from all 
leukocytes and proliferation (Ki67+) of T cells (*p < 0.05, ***p < 0.001, X2 exact test, two-tailed). Pan-Epi, pan-
epithelium.
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similar AR expression as AMACR+ cancer cells (0.113 vs. 0.112, p = 0.191). Overall, we found an inverse corre-
lation between AR and AMACR in cancer cells (Pearson r = −0.26, p < 0.00001), but not in benign luminal cells 
(r = −0.05, p < 0.00001). As expected, the mean expressions of the epithelial markers, CK18, CK8, and Pan-Epi 
were weak in stromal cells.
Discussion
Advances in the understanding of tumour biology are rapidly changing the pathology field enabling better 
prognostics and new therapies. However, the tools to study cellular and molecular components of the tumour 
microenvironment need further development. In particular, there is a need for open-source systems and meth-
ods that would allow high-resolution whole-slide multiplexed readouts. For instance, it has been shown that 
analysis of small regions of interest causes significant variation and error in the assessment of molecular markers 
in breast cancer20. Although there has been a surge of novel technologies for sophisticated mIHC, the methods 
have limitations regarding their applicability for large-scale studies with quantitative whole-slide analysis either 
due to expensive instrumentation, the time needed to acquire whole-slide data, or due to antibody modifications 
required prior to the assay. Currently, there are no publications describing >5-plex mIHC assay design with 
high-resolution whole-slide imaging, open-source whole-slide image analysis at cell-level resolution, and the 
possibility to implement new targets rapidly (see Supplementary Table S3 for a summary).
Here, we present an mIHC method for the whole-slide analysis of immune cells and epithelial cells in human 
prostate cancer combining fluorescent and chromogenic detection of six proteins and nuclei in the same tissue 
section. As the system is designed for a fixed set of secondary reagents and unlabelled primary antibodies, intro-
ducing new primary antibodies is rapid allowing flexible design of custom mIHC target panels. The presented 
mIHC system enables not only a multiplexed analysis but also an open-source high-resolution digital image 
analysis across entire tissue sections (Fig. 5).
In the first proof-of-concept for immune cell detection, we detected 128,894 cells in a single whole tissue 
section of a prostate tumour. We found significantly less regulatory T cells and helper T cells in the tumour epi-
thelium as compared to the stroma. Nevertheless, both cell types showed substantially higher proliferation rate 
in the epithelium than in the stroma, which could be a reflection of immunosuppressive microenvironment in 
this patient case, since regulatory T cells have been shown to suppress immune system in cancer23. However, as 
we studied only a single patient case to present the technical proof-of-concept, no biological conclusions can be 
drawn. Nevertheless, this type of single immune cell classification and analysis in the different tissue compart-
ments is only possible by using multiplexed detection in the intact tissue context on whole-slides.
Figure 4. Tissue cytometry of epithelial cells (patient 2) in prostate cancer. (a) Cell class distribution and 
(b) AMACR and Pan-Epi expression in all cells (n = 83,558) with AMACR positivity threshold indicated 
(dashed line). (c) Expression profile of Pan-Epi, AMACR, and AR differs between the four cell classes. (d) AR 
expression in AMACR− cancer cells, AMACR+ cancer cells, and in AMACR− benign luminal epithelial cells 
(***p < 0.001, non-parametric Kolmogorov-Smirnov test). Boxplots indicate median and quartiles. AMACR, 
alpha-methylacyl-CoA racemase; AR, androgen receptor; Pan-Epi, pan-epithelium.
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In the second proof-of-concept, we report an automatic classification of individual prostatic epithelial cells as 
benign or cancerous based on the epithelial marker profiling. Here, the detection of basal cells using CK5 and p63 
is important, as the loss of basal cells is a diagnostic hallmark of PCa24. In addition, several prognostic biomarkers 
have been suggested for PCa25,26, but few have been translated in the clinic. Thus, PCa diagnostics and prognostics 
could benefit from an automatic whole-slide analysis combining readouts for the absence of basal cells and for the 
expression of key biomarkers, such as AMACR and AR, at single cell level. To demonstrate this, we detected and 
automatically classified 83,558 cells in the whole tissue section as stromal, basal epithelial, benign luminal epithe-
lial, or cancer cells, and then measured the expression of CK8, CK18, AMACR and AR in all the cells quantita-
tively. We found that the expression of AR and CK18 were elevated in cancer cells as compared to benign luminal 
cells or basal cells, which has been also reported earlier27,28. However, the expression of AR in AMACR− cancer 
cells was remarkably stronger than in either AMACR+ cancer cells or AMACR− benign epithelial cells, whereas 
AMACR+ cancer cells and AMACR+ benign luminal cells showed similar AR expression. As AMACR positivity 
in the prostate epithelial cells is a proposed marker for a pre-malignant prostatic intraepithelial neoplasia (PIN)29, 
our data shows that AR expression is pronounced only in cancer cells but not in PIN lesions in this patient. Again, 
even though extensive biological conclusion cannot be presented based on a single patient case, this type of tissue 
cytometry data from solid tumours can only be obtained through in situ multiplexed assays.
While the concept of mIHC in FFPE tissues is established, few studies have addressed the compatibility of 
antibodies for multiplexed IHC assays2. As it is important to eliminate false-positive results in assays where the 
same secondary reagent is applied subsequently (e.g., the commercially available Opal system by PerkinElmer)22, 
we tested whether primary antibodies could be detached from tissues or denatured in situ by incubation in a 
hot buffer, mimicking the conditions in the HIER procedure during IHC. Surprisingly, we did not observe sub-
stantially reduced signal from the anti-CK5/anti-rabbit-AlexaFluor488 or anti-CK8/anti-mouse-AlexaFluor647 
antibody complexes when secondary antibodies were applied on the sections before exposing the slides to hot 
buffer. However, except for E-cadherin and Ki67 antibodies, the signal was completely absent if the slides were 
exposed to hot buffer before applying secondary antibodies on the sections, even at high antibody concentrations. 
These findings imply that neither primary nor secondary antibodies are detached from the tissue but the antibody 
complex is denatured in the tested HIER conditions, and may have implications in mIHC methods relying on 
antibody stripping. Wahlby et al.2 showed similar results for nuclear antigens using FITC and CY3 fluorochromes. 
However, the tissue integrity and antigenicity was compromised as their Sequential Immunofluorescence Staining 
(SIFS) assay required fluorescence removal after each round of staining by exposing the slides in harsh acidic 
conditions. In contrast, as our assay design does not require fluorescence removal/bleaching at any step, we can 
use milder conditions to denature primary antibodies potentially preserving better the epitope antigenicity and 
tissue integrity. Based on our results, we propose that any antibody showing incomplete denaturation can only be 
Figure 5. Summary of key aspects of the described mIHC platform combining (a) rapid implementation of 
new antibodies for targets of interest, (b) >5-plex mIHC assay design, (c) high-resolution whole-slide image 
acquisition, and (d,e) open-source high-resolution whole-slide image analysis.
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applied in the last round of primary antibodies whenever the same secondary antibody is used more than once 
during the mIHC assay. We recommend, that the described antibody tests should be performed to verify dena-
turation of all primary antibodies prior to application in mIHC assays that utilize indirect detection and multiple 
staining rounds.
Labelling of the primary antibodies for mIHC assays, independent of the imaging modality, complicates assay 
design. For example, fluorescence dye cycling5,17 or mass spectrometry10–12 use directly labelled primary antibod-
ies, which require rigorous validation after the labelling reaction. In contrast, mIHC methods that utilize indirect 
detection employing secondary reagents to detect unlabelled primary antibodies overcome the pitfalls of the 
labelling issues, but in contrast, are limited in terms of the degree of multiplexing. For all methods utilizing indi-
rect detection, the number of primary antibody host species limited the degree of multiplexing until the invention 
of tyramide signal amplification (TSA)18,22. TSA has stretched the limits of indirect multiplexing by introducing 
covalent fluorochrome attachment that allows application of primary antibodies from the same host species on 
multiple subsequent cycles. By using a combination of multispectral imaging and TSA, up to seven targets have 
been detected in the same tissue section9,16,22. However, multispectral imaging is not practical for whole-slide 
analytics at high resolution across entire tissue specimen. Nevertheless, the most important aspect of indirect 
detection is the possibility to use commercially available validated primary antibodies without labelling.
Due to strong autofluorescence of formalin-fixed tissues, especially in the blue-green range of the emission 
spectrum3, the fluorescence signal-to-background ratios are not high enough without signal amplification and/
or autofluorescence image compensation. We employed TSA for AlexaFluor488 and AlexaFluor555 to overcome 
tissue autofluorescence in the blue-green spectral region. Additionally, we detected a pair of primary antibodies 
from different host species using AlexaFluo647 and AlexaFluor750 without TSA, as the tissue autofluorescence 
is low in the red/infrared region. This approach minimizes heating steps during the assay preserving the tissue 
integrity and making the staining process faster. With this assay design, we achieved 5-plex fluorescence assay 
with only two heating steps and 8-plex assay with one additional heating step for a triple colour chromogenic 
staining (See Supplementary Information for a detailed protocol). This differs from the published methods utiliz-
ing TSA6,8,9,22, where a heating step is applied prior to every single primary antibody, hence making them slower 
and potentially compromising the tissue integrity.
Fluorescence channel crosstalk (also known as bleed-through or cross-over) should be addressed when mul-
tiple fluorochromes are applied, irrespective of signal intensity. A common solution for reducing crosstalk is 
unmixing of the individual fluorochrome signals from the mixed image data after image acquisition (also known 
as de-convolution or bleed-through/cross-over compensation, see Stack et al.8 for a comprehensive review on 
the topic). However, an accurate spectral unmixing requires a library of pure fluorescence spectra, which should 
match the actual multiplexed sample as closely as possible in terms of spectral characteristics and fluorescence 
intensity. Furthermore, the multispectral imaging produces large datasets, even ten times larger than images 
acquired using band-pass filters (personal communication with Dr. Bruun at the Institute for Cancer Research, 
Oslo University Hospital, Norway), which means long image acquisition times and requires intensive computing 
for analysis, thus limiting the use of these methods for high-resolution whole-slide analytics. In order to increase 
image acquisition speed and to reduce raw data output as well as to obviate the need for spectral unmixing, we 
utilized standard optical band-pass filters including NIR detection delivering spectrally resolved raw data already 
in single image acquisition step for up to five fluorochromes (AlexaFluor488, -555, -647, -750, and Hoechst).
We performed automated whole-slide image analysis using CellProfiler platform30. The open-source 
CellProfiler software is widely used for single cell segmentation and feature extraction, and has been previously 
applied for tissue image analysis with high efficacy and accuracy31,32. Several characteristics of FFPE tissue make 
the cellular segmentation in image analysis challenging, as has been already discussed earlier32. Firstly, the cell 
morphology is very heterogeneous due to large number of different cell types and partial cutting of the cells in tis-
sue sections. Secondly, the image of a tissue section is only a 2D projection of 3D structure. Thirdly, cells in solid 
tissue are usually close to each other forming clumps and/or overlapping with each other. However, regardless of 
the issues with cell segmentation accuracy, automated methods hold many advantages over manual cell detection 
and classification. Manual tissue image analysis is subjective, often includes large variation between experts, and 
is impractical when analysing whole tissue sections with hundreds of thousands of cells. For these reasons, we 
have applied automated image analysis methods. We tested various segmentation algorithms using sub-images 
of both antibody panels and selected the most accurate segmentation based on expert visual interpretation of 
the result. The signal-to-noise ratio of nuclei staining was high making the initial segmentation based on nuclei 
thresholding simple. To design our pipeline as generic as possible, we utilized automatic thresholding (Otsu33) 
instead of manual thresholding. Due to the large tile images with thousands of cells per image, the statistical auto-
matic segmentation avoided failures caused by low cell counts in an image.
As our aim was to design an open-source mIHC platform with easy accessibility and implementation, we 
designed the cell segmentation pipelines as simple and as generic as possible. Given that image analysis is a com-
promise between computational complexity, accuracy, and usability, we decided to apply generic object splitting 
solutions available in CellProfiler based on widely used watershed segmentation from seed points34 at both local 
intensity peaks (nuclei) or at peaks in distance transformed binary image (glands). More complex segmenta-
tion methods allow segmentation of overlapping cells35, however, most of these methods are computationally 
demanding. We also experimented with geodesic active contours36 for gland segmentation, which did not, how-
ever, improve the segmentation result.
In conclusion, we describe an 8-plex mIHC platform for systems pathology enabling quantitative whole-slide 
analysis at single-cell resolution on FFPE material. The presented platform is not limited in terms of speed, 
accessibility, or resolution for true whole-slide analysis. Furthermore, as the system is designed for open-source 
platforms and for a fixed set of secondary reagents, its implementation is straightforward in a regular histopa-
thology laboratory, therefore providing a practical solution for whole-slide mIHC. We believe that the unique 
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combination of 8-plex mIHC assay design, robust whole-slide image acquisition and image analysis, and fully 
customisable antibody panels makes this system a viable platform for pathology research.
Methods
Patient samples. FFPE samples (prostate cancer samples referred as patient 1 and patient 2) were obtained 
from the Department of Pathology at the Helsinki University Central Hospital (HUCH). Formalin fixation and 
paraffin embedding were performed in the central laboratory of HUCH according to standard procedures. The 
samples were anonymous and all patient-related data and unique identifiers were removed, and therefore, the 
study did not require ethical approval, thus complying with Finnish legislation regulating human tissues obtained 
for diagnostic purposes (act on the use of human organs and tissue for medical purposes 2.2.2001/101). The FFPE 
blocks were cut as 3.5 µm sections on Superfrost objective glass slides (Kindler O Gmbh, Germany) using Microm 
355 S microtome (Thermo Scientific, Waltham, MA), which were dried overnight at +37 °C and stored at +4 °C. 
For long-term storage, slides were stored at −20 °C.
Immunohistochemistry (IHC). All antibodies used in this study are listed in Table 1. See Supplementary 
Information for a list of publications for the used antibodies.
Chromogenic IHC. See full protocol in Supplementary Information. Shortly, we removed paraffin from the 
slides in xylene and subsequent decreasing alcohol series ending in water, and performed heat-induced epitope 
retrieval (HIER) in hot buffer (+99 °C) for 20 min (PT Module, Thermo Fisher Scientific, Waltham, MA). After 
HIER, we blocked endogenous peroxide activity in 0.9% H2O2 solution for 15 min at room temperature (RT). 
Protein blocking was performed in 10 mM Tris-HCl buffered saline pH 7.4 (TBS) with 10% normal normal 
goat serum (TBS-NGS) 30 min at RT before primary antibody was applied on the slides. After primary anti-
bodies, we applied anti-mouse or anti-rabbit horseradish peroxidase (HRP) conjugated secondary antibodies 
(Immunologic, Netherlands) for 30 min at RT to detect primary antibodies. We applied 3,3′-Diaminobenzidine 
(DAB; Immunologic) according to manufacturer’s instructions for 5 min to visualize antibody complexes and 
counterstained the slides using 1:10 water dilution of Mayer’s haematoxylin (Dako, Carpinteria, CA) for 1 min. 
We dehydrated the samples in increasing alcohol series and xylene, applied coverslips, and imaged the slides as 
described below in the Imaging section.
Fluorescence IHC. See Supplementary Information for a full, detailed protocol. We processed the slides 
as described above, except that after primary antibody, we applied AlexaFluor555 or AlexaFluor647 
fluorochrome-conjugated secondary antibodies (Thermo Fisher Scientific) as 1:300 dilutions for 30 min to detect 
the primary antibody and used 1 µg/ml Hoechst 33342 (Sigma-Aldrich, St. Louis, MO) for nuclear counterstain. 
After application of coverslips, we imaged the slides as described below in the Imaging section. All antibody 
dilutions were made in TBS-NGS. We washed the slides three times 5 min at RT after each step in TBS with 0.05% 
Tween20 (TBST).
Target Species Vendor Cat number Dilution1 Concentration (µg/ml) HIER buffer Label (enzyme) Incubation Panel
CK18 ms SantaCruz 6259 2000 0.1 Tris-EDTA TSA488 o/n EPI
CK8 ms Invitrogen 18–0185z 2000 0.11 Tris-EDTA TSA555 o/n EPI
p63 rbt Abcam 124762 1000 0.87 Tris-EDTA AlexaFluor647 90 min EPI
CK5 rbt Abcam 52635 400 (2000) 0.88 Tris-EDTA AlexaFluor647 90 min EPI
E-cadherin ms BD biosciences 610182 1000 (10000) 0.25 Tris-EDTA AlexaFluor750 90 min EPI
PanCK ms Abcam 7753 200 (2000) 5 Tris-EDTA AlexaFluor750 90 min EPI
PanCK ms Invitrogen 18–0132 200 (2000) 0.18 Tris-EDTA AlexaFluor750 90 min EPI
AR rbt SantaCruz 13062 2000 0.1 Tris-EDTA VinaGreen (HRP) 90 min EPI
AMACR ms Abcam 63340 2000 N/A, LOT GR154665-12 Tris-EDTA Liquid Permanent Red (AP) 90 min EPI
FoxP3 ms Abcam 20034 500 2 Tris-EDTA TSA488 o/n IC
CD4 ms Abcam 133616 3000 0.05 Tris-EDTA TSA555 o/n IC
CD8 ms BioSB 5174 100 (1000) N/A LOT5174JDL05 Tris-EDTA AlexaFluor750 90 min IC
CD45 rbt CellSignalling 13917 100 (500) N/A, LOT 1 Tris-EDTA AlexaFluor647 90 min IC
Ki67 rbt Abcam 92742 5000 0.14 Tris-EDTA Liquid Permanent Red (AP) 90 min IC
E-cadherin ms BD biosciences 610182 10000 0.03 Tris-EDTA VinaGreen (HRP) 90 min IC
PanCK ms Abcam 7753 2000 0.5 Tris-EDTA VinaGreen (HRP) 90 min IC
PanCK ms Invitrogen 18–0132 2000 0.02 Tris-EDTA VinaGreen (HRP) 90 min IC
Table 1. Primary antibodies, fluorochromes, and chromogens used in the study. All antibodies are 
commercially available. See also Supplementary Figure S5 for primary antibody denaturation testing. AMACR, 
alpha-methylacyl-CoA racemase; AR, androgen receptor; CK, cytokeratin; EPI, epithelial; HIER, heat-induced 
epitope retrieval; HRP, horse-radish peroxidase; IC, immune cell; ms, mouse; o/n, overnight; rbt, rabbit; TSA, 
tyramide signal amplification. 1Brackets indicate the optimized dilution for chromogenic/TSA-amplified 
detection.
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Primary antibody validation for mIHC. Fluorochrome heat-stability test. We performed fluores-
cence IHC as described above by applying anti-cytokeratin 5 (anti-CK5; 1:600 dilution) and anti-cytokeratin 
8 (anti-CK8; 1:100 dilution) primary antibodies on prostate tissue sections and detected them using 
AlexaFluor555-conjugated goat anti-rabbit and AlexaFluor647-conjugated goat anti-mouse secondary antibod-
ies, respectively. After image acquisition (see Imaging section below), slides were incubated in +99 °C Tris-EDTA 
(pH 9) for 20 minutes and fluorescence images were acquired again. Subsequently, we incubated the slides in 
+100 °C 25 mM glycine (pH 2) with 2% (w/v) sodium dodecyl sulfate (SDS) for 4 minutes and re-acquired fluo-
rescence images.
Antibody testing. We tested all primary antibodies on prostate cancer and lymph node FFPE samples. The anti-
bodies were tested as following: 1) To find optimal concentration, antibodies were tested in different dilutions 
(typically three to four different dilutions, starting from vendor’s recommendation for IHC) and chromogen 
staining result was assessed visually. 2) The selected concentration was also used for tyramide signal amplified 
staining. 3) For non-amplified fluorescence detection, we used five- or ten-fold concentration compared to the 
concentration used in non-amplified staining. The concentration resulting in higher signal-to-background ratio 
based on visual assessment was selected as concentration for mIHC.
For heat-induced denaturation, we applied primary antibodies on tissue sections and subsequently heated 
the slides in +99 °C HIER buffer for 20 minutes. All slides were processed according to the chromogenic IHC 
protocol as described above, except that slides were heated in hot buffer after primary antibodies were applied on 
the slides. Heat control slides were stained equally but without the heat exposure.
Multiplexed immunohistochemistry (mIHC). The 8-plex mIHC method combined fluorescence and 
chromogenic detection (Supplementary Fig. S1 and S2). Tissue sections were treated according to the IHC pro-
tocol as described above until the application of primary antibodies. See the full and detailed mIHC protocol 
in Supplementary Information and antibodies used in Table 1. Shortly, after HIER and protein blocking, we 
applied the first primary antibody and used tyramide signal amplification (TSA) for AlexaFluor488 (PerkinElmer, 
Waltham, MA) on the slides according to manufacturers instructions. An HRP conjugated host-specific second-
ary antibody was diluted 1:10 in TBST and incubated for 45 min at RT. After secondary antibody, tyramide reac-
tion was incubated exactly 15 min at RT. The HRP activity was abolished using hydrogen peroxide and sodium 
azide. After the attenuation of HRP, we performed identical TSA procedure but now with primary antibody 
from different host and AlexaFluor555 (PerkinElmer). After the second TSA cycle, we performed HIER step for 
60 min and applied a pair of primary antibodies raised in different species to detect additional two targets. We 
detected the primary antibodies with AlexaFluor647 and AlexaFluor750 fluorochrome-conjugated secondary 
antibodies (Thermo Fisher Scientific) and counterstained nuclei using Hoechst 33342. We applied ProLong Gold 
mountant (Thermo Fisher Scientific), coverslipped the slides, and acquired whole-slide fluorescence images using 
five fluorescence channels. After fluorescence imaging, we detached the coverslip and performed another HIER 
step. After blocking of the slides, we applied a pair of antibodies raised in different species for 90 min at RT. We 
detected the primary antibodies using alkaline phosphatase (AP) and HRP conjugated secondary antibodies 
(Immunologic). The secondary antibodies were mixed 1:1 and incubated for 30 min at RT. The antibody com-
plexes were detected using red (Liquid Permanent Red; Dako) and green (VinaGreen; Biocare Medical, Concord, 
CA) chromogens according to manufacturer´s instructions, respectively. We performed chromogen reactions 
subsequently for 8 min at RT, first for VinaGreen and then for Liquid Permanent Red. The slides were washed 
for 1 min in water after each reaction. We counterstained the slides with haematoxylin (1:10 water dilution, 30 s). 
After mounting (Pertex) and coverslipping, we acquired brightfield images as described below. See Table 1 for 
antibodies and fluorochromes used in the study.
mIHC performance evaluation. Prostate cancer tissue was stained using the mIHC protocol pairwise for FoxP3 
(AlexaFluor488) and CD4 (AlexaFluor555) in patient 1, CD4 (AlexaFluor555) and CD45 (AlexaFluor647) in 
patient 1, and PanEpi (AlexaFluor647), and CK5 + p63 (AlexaFluor750) in patient 2.
Imaging. All digital, whole-slide fluorescence and brightfield images were acquired at 0.33 µm/pixel or 
0.22 µm/pixel resolution, respectively, using Pannoramic P250 Flash II whole-slide scanner (3DHistech, Hungary) 
equipped with Zeiss Plan-Apochromat 20x objective (NA 0.8) and a modified Spectra X light engine (Lumencor 
Inc., Beaverton, OR). In the modified light engine the teal LED was replaced with NIR LED, which enabled 
imaging in the NIR spectral region. The slide scanner stage and optical light-paths were calibrated and aligned 
by manufacturer (3DHistech) and re-adjusted on-site at scanner installation. The light engine was calibrated at 
Lumencor. Automatic focusing (default factory settings) was used for both fluorescence and brightfield imaging. 
For fluorescence imaging, we used DAPI, FITC, CY3, CY5, and CY7 filter sets with compatible LED light sources 
in the Spectra X engine. See Supplementary Table S1 for optical filters, LED light source specifications, and expo-
sure times used for each fluorochrome/channel. After image acquisition, images were converted to JPEG2000 
format (95% quality). Fluorescence images were stored as 8-bit grayscale images and brightfield images as stand-
ard RGB images. For mIHC performance evaluation, the stained prostate cancer tissues were imaged as described 
above using exposure times of 30 ms for FITC channel, 40 ms for CY3 channel, 50 ms or 100 ms for CY5 channel, 
and 150 ms for CY7 channel.
For the antibody detachment test, snapshot fluorescence images were acquired using AxioImager.Z2 (Zeiss, 
Germany) microscope equipped with Zeiss Plan-Apochromat 20x objective (NA 0.8), CoolCube1 CCD camera 
(MetaSystems, Germany), and HXP 120 metal-halide light source. Exposure time was fixed to 300 ms and CY3 
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and CY5 filter cubes were used for imaging of AlexaFluor555 and AlexaFluor647 fluorochromes, respectively. We 
selected a representative tissue area manually for the detachment analysis.
Colour de-convolution and image registration. We separated the different chromogen components in 
the VinaGreen-LiquidPermanentRed-Haematoxylin-stained samples with a colour de-convolution algorithm37 
after 1:4 downscaling of the whole-slide images. For registration of the brightfield and fluorescent channels, we 
applied Speeded-Up Robust Features (SURF)38 for keypoint detection and description. In the estimation of the 
geometric transformation, we used downscaled haematoxylin (1.76 µm/pixels) and DAPI (2.56 µm/pixels) chan-
nels, and set the haematoxylin channel as the reference image for descriptor matching. Registered images had an 
image resolution of 0.64 µm/pixels. Both colour de-convolution and image registration were implemented with a 
numerical computing environment (MATLAB, MathWorks, Natick, MA, U.S.).
Image processing, cell segmentation and classification. Antibody and fluorochrome heat-stability 
test. We analysed 8-bit grayscale images using ImageJ64 (1.48 v). We segmented cell objects as following: Image 
was converted to a binary mask using default setting, after which standard built-in dilation and watershed oper-
ations were applied to segment out cell objects. Fluorescence intensity within objects was calculated as mean 
intensity value per object area (pixels) in objects larger than 100 pixels in size. Data was plotted using Excel for 
Mac 2011.
mIHC performance evaluation. Fluorescence intensities were measured in 8-bit gray-scale images pairwise for 
neighbouring channels (FITC-CY3, CY3-CY5, and CY5-CY7). We selected areas for measurements with min-
imal antibody (and fluorochrome) co-localisation in the measured pixels. The average background signal was 
measured from at least 1,000 visually blank pixels in each image. Signal-to-background ratio (S/B) was defined 
as background-corrected specific fluorescence intensity (S) divided by the background signal (B). All data was 
plotted using Excel for Mac 2011.
mIHC. We used in-house developed MATLAB scripts for pre- and post-processing of the image data, 
and CellProfiler 2.1.2 software platform (24) for object segmentation, measurements and classification 
(Supplementary Fig. S7, code and pipelines available at https://github.com/lopaavol/mihc-suppl-software). 
As a pre-processing step, the digital whole-slide images (depth 8-bit, resolution 0.64 µm/px) were tiled into 
2048 × 2048 pixel regions-of-interests (ROIs) to reduce the memory demand during the image analysis. Since 
whole epithelial glands were needed for classification of the cells, all ROIs were padded to 10240 × 10240 pixel 
images. We confirmed that the epithelial glands, which were inside the ROI were also fully included in the padded 
images.
Next, we segmented epithelial glands and all cells for single cell analysis and classification. First, epithelial 
glands (Pan-Epi) were segmented using global (Immune cell panel, patient 1) or adaptive (Epithelial cell panel, 
patient 2) Otsu thresholding (29). Adaptive thresholding was used in epithelial cell analysis to reduce the effect 
of non-uniform background. Touching glands were separated using watershed segmentation. Second, cells were 
segmented from the images of nuclei stained channel using adaptive Otsu thresholding. The range for diameter of 
nucleus was set to 20–80 pixels. Larger clumps were split based on watershed segmentation with intensity peaks 
as seed points. Third, global Otsu thresholding was used to create a mask from CD45 imaged channel (patient 1) 
and CK5 + p63 channel (patient 2). After object segmentation, we calculated intensity of all markers and mean 
radius in the detected cells. The intensity values (scale 0–255) were calculated as mean intensity values per object 
area (pixels), and were normalized yielding values 0–1 for each marker. A cell was considered positive for a given 
marker if the expression was higher than one standard deviation (SD) above the mean expression in all cells. For 
Ki67, we used a threshold three SDs above the mean intensity of all cells to avoid false positive cells due to low 
number of Ki67+ cells in the samples. Cells were automatically classified based on the epithelial gland segmenta-
tion and masks for CD45 (patient 1) or CK5 + p63 (patient 2).
In the mIHC of immune cell panel (patient 1), nuclei were first classified either as being inside or outside of 
an epithelial gland. Based on the CD45 mask image, nuclei were further classified as epithelial leukocytes (inside 
glands) or stromal leukocytes (outside glands). The rest of the cells inside the glands were classified as epithelial 
cells and the rest of the cells outside the glands as other cells. CD45+ leukocytes were further classified as T regu-
latory (CD4+FoxP3+CD8−), T helper (CD4+FoxP3−CD8−), or T effector (CD8+CD4–FoxP3−) cells.
In the epithelial cell analysis (patient 2), we classified the glands first either as benign epithelial glands or 
cancer glands based on the CK5 + p63 expression indicating presence or absence of basal cells in a given gland. 
Nuclei inside cancer glands were classified as nuclei of cancer cells. Nuclei inside benign epithelial glands were 
further classified as nuclei of basal cells or benign luminal cells based on the overlap (area overlap minimum 10%) 
with the CK5 + p63 threshold mask. Nuclei outside glands were classified as nuclei of stromal cells.
After segmentation, measurements and classification of cells, the results and images were stitched together as 
a whole-slide image and result data. We filtered out cells with centroids in padded region to remove duplicates 
from the results, and stitched central 2048 × 2048 pixel region from all images together as a whole-slide image for 
classification visualization. No cells were lost during tiling and stitching as a result of using overlapping padded 
image regions for analysis.
Statistical methods. Fisher’s exact test (X2, two-tailed, exact method) was used to compare cell counts 
between two groups. Non-parametric Kolmogorov-Smirnov (KS) test was used to compare marker expressions 
between two cell populations (non-normally distributed data). Correlation between two continuous variables 
was calculated using Pearson’s correlation coefficient (r). P-values < 0.05 were considered statistically significant.
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Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request. Image analysis code and pipelines are available at https://github.
com/lopaavol/mihc-suppl-software.
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